Lexicon Pharmaceuticals/LXRX

$1.62

-
-
1D1W1MYTD1YMAX

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Ticker

LXRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Lonnel Coats

Employees

285

Headquarters

The woodlands, United States

LXRX Metrics

BasicAdvanced
$586M
Market cap
-
P/E ratio
-$0.83
EPS
1.37
Beta
-
Dividend rate
$586M
1.36794
$3.73
$0.92
3.7M
15.584
15.562
34.574
34.574
-11.46%
-66.76%
-102.73%
-72.21%
253.371
1.381
2.397
1,734.13%
-31.41%
-63.12%

What the Analysts think about LXRX

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
224.07% upside
High $10.00
Low $2.00
$1.62
Current price
$5.25
Average price target

LXRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-4,390.9% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.1M
57.14%
Net income
-$48M
-2.82%
Profit margin
-4,390.9%
-38.16%

LXRX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.27%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.21
-$0.20
-$0.20
-
Expected
-$0.17
-$0.21
-$0.22
-$0.20
-$0.19
Surprise
25.89%
-2.21%
-7.94%
1.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals (LXRX) has a market cap of $586M as of May 28, 2024.

What is the P/E ratio for Lexicon Pharmaceuticals stock?

The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of May 28, 2024.

Does Lexicon Pharmaceuticals stock pay dividends?

No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Lexicon Pharmaceuticals dividend payment date?

Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Lexicon Pharmaceuticals stock price target?

The target price for Lexicon Pharmaceuticals (LXRX) stock is $5.25, which is 224.07% above the current price of $1.62. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Lexicon Pharmaceuticals stock

Buy or sell Lexicon Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing